The FDA approved Reata Pharmaceuticals Inc’s (NASDAQ:RETA) Skyclarys (omaveloxolone) for Friedreich’s ataxia in adults and adolescents aged 16 and older. With…
"I hope this is resolved fairly to a company that helped the most in the recovery."
– José Ortiz, former PREPA CEO
"PREPA would often find reasons not to pay Cobra – by, for instance,